Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice.

The intraperitoneal (i.p.) administration of cisplatin (CDDP) is one of the most effective therapies for cancers that are confined to the abdominal cavity. However, the effect of fluid osmolarity on the therapeutic efficacy of i.p. administration of CDDP has not been well established. In the current study, hypotonic (154 mosmol 1-1), isotonic (308 mosmol 1-1) and hypertonic (616 mosmol 1-1) solutions of CDDP were prepared for an evaluation of their therapeutic efficacy in an experimental system. After i.p. administration, uptake of CDDP in vivo by tumor cells in hypotonic solution was significantly greater than in isotonic or hypertonic solution. The 50% lethal dose (LD50) value of CDDP in hypotonic solution (12.1 mg kg(-1)) was lower than that in isotonic solution (16.9 mg kg(-1)) and than that in hypertonic solution (28.6 mg kg(-1)). However, when a dose equal to one-half of the LD50 was administered in each solution to mice with i.p. tumours, survival of mice given the CDDP in hypotonic solution was significantly prolonged as compared with the survival of the other mice. These results demonstrate that the therapeutic efficacy of i.p. CDDP in mice is augmented when the drug is administered in hypotonic solution.

[1]  J. Mcvie,et al.  Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. , 1989, Cancer research.

[2]  N. Saijo,et al.  Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. , 1990, Cancer research.

[3]  A. Guarino,et al.  Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. , 1977, Biochemical medicine.

[4]  Y. Maehara,et al.  Intraperitoneal cisplatin during surgery for gastric cancer and peritoneal seeding. , 1993, Anticancer research.

[5]  P. Daley-Yates,et al.  Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin. , 1984, Biochemical pharmacology.

[6]  C. Litterst.  Alterations in the toxicity of cis-dichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration. , 1981, Toxicology and applied pharmacology.

[7]  W. Cunliffe,et al.  early postoperative i ntraperitoneal chemotherapy , 2005 .

[8]  M. Ruevekamp,et al.  Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action. , 1991, Biochemical pharmacology.

[9]  S. Aamdal,et al.  Reduced antineoplastic activity in mice of cisplatin administered with high salt concentration in the vehicle. , 1984, Journal of the National Cancer Institute.

[10]  R. Ozols.  Intraperitoneal chemotherapy in the management of ovarian cancer. , 1985, Seminars in oncology.

[11]  P. Disaia,et al.  Intraperitoneal cisplatin: comparison of antitumor activity and toxicity as a function of solvent saline concentration. , 1989, Gynecologic oncology.

[12]  D. J. Finney.  Graphical estimation of relative potency from quantal responses. , 1952, The Journal of pharmacology and experimental therapeutics.

[13]  A. B. Campbell,et al.  Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. , 1983, Cancer treatment reports.

[14]  B. Rosenberg.  Anticancer activity of cis-dichlorodiammineplatinum(II) and some relevant chemistry. , 1979, Cancer treatment reports.

[15]  J. Mcvie,et al.  Experimental and clinical status of intraperitoneal chemotherapy. , 1990, European journal of cancer.

[16]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[17]  S. Buys,et al.  Effect of osmotic pressure on uptake of chemotherapeutic agents by carcinoma cells. , 1990, Cancer research.

[18]  K. Brown,et al.  Ultrafiltration in serum protein binding determinations. , 1981, Journal of pharmaceutical sciences.

[19]  E. Smith,et al.  The effect of reduced osmolarity on platinum drug toxicity. , 1989, British Journal of Cancer.

[20]  A. Eastman.  The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. , 1987, Pharmacology & therapeutics.

[21]  N. Oleinick,et al.  Modification of DNA damage in transcriptionally active vs. bulk chromatin. , 1986, International journal of radiation oncology, biology, physics.

[22]  G. Setterfield,et al.  Effects of low salt concentration on structural organization and template activity of chromatin in chicken erythrocyte nuclei. , 1971, Experimental cell research.